Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The largest and longest clinical trial of its kind has found that resurfacing the kneecap during total knee replacement is likely to be the most cost-effective approach for patients and healthcare systems over the long term.

Knee joint showing the position of the patella or kneecap

Researchers from the University of Oxford and the University of Aberdeen followed more than 1,700 patients for 20 years as part of the KAT (Knee Arthroplasty Trial) study, making it the longest randomised controlled trial ever conducted in knee orthopaedics.

Total knee replacement is one of the most common and effective operations performed in the NHS. Although it is generally highly successful, up to one in five patients continue to experience pain or reduced function after surgery. Many of these poor results are thought to relate to the movement between the kneecap and the underlying knee replacement.

One potential solution is kneecap resurfacing, which involves replacing the damaged underside of the kneecap with a smooth artificial surface during knee replacement surgery. However, whether surgeons should routinely perform this procedure has long been debated, and practice varies widely both within the UK and internationally.

The research was a collaboration between the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences and the Nuffield Department of Population Health, both at the University of Oxford, and the Aberdeen Centre for Evaluation (ACE) at the University of Aberdeen. 

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences website.

 

 

 

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience